Infertility Clinical Trial
— PREDHSOOfficial title:
Vascular Cell Activation Throughout Ovarian Hyperstimulation for In Vitro Fertilisation: Role of Cell-Derived Microparticles in the Adverse Outcomes
Verified date | February 2017 |
Source | Poissy-Saint Germain Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Introduction: Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic phenomenon, poorly
understood and difficult to predict, complicating intense ovarian stimulation cycle. The
most severe symptoms, which associate vascular permeability disorders and
hypercoagulability, occur in 0.2 to 1% of the cases and often require intensive care.
Activation of endothelial, platelet, erythrocyte or leukocyte cells trigger the release of
small specific vesicles, called microparticles, used as markers.
Classically leading to endothelial dysfunction and hypercoagulability, the endothelial
activation phenomenon could constitute the main cause of OHSS or help predict its severity,
as established for various other diseases (cerebral stroke, infarct and lupus…). However, so
far, this endothelial activation role has never been studied.
Objectives:
Evaluate the serum level of microparticles as a predictor of adverse outcomes; correlate it
to hypercoagulability and changes of endothelial permeability associated with this syndrome.
Methodology: Prospective Pilote Cohort study, evaluating before and throughout the ovarian
stimulation cycle (6 samples/patient), the serum modulation of:
- Endothelial activation markers (endothelial-derived microparticles, E-selectin)
- Procoagulant markers (microparticles from platelet, erythrocyte or leukocyte origin,
Von Willbrand factor, thrombin-antithrombin complex, prothrombin fragment 1+2)
- Endothelial disjunction marker (soluble CD 146) A group of 50 patients will be assessed
Techniques: Flow cytometry for measurement of microparticles expressing non specific
(Annexin V) and cell specific surface determinants (CD 31, CD 41, CD 45 or glycophorin
A). Use of commercial kits for other serum markers.
Status | Completed |
Enrollment | 50 |
Est. completion date | February 1, 2017 |
Est. primary completion date | January 2, 2015 |
Accepts healthy volunteers | |
Gender | Female |
Age group | 18 Years to 43 Years |
Eligibility |
Inclusion Criteria: - Between 18 and 35 years old - With Health Insurance - Scheduled for their first ovarian stimulation in an IVF or ICSI program in our centre - Whose blood samples will be collected in our hospital Exclusion Criteria: - Suffering or having suffered from a disease likely to alter their vascular system and thus modulate their rates of microparticles: - auto-immune disease (systemic lupus erythematosus26, antiphospholipid syndrome) - cardiovascular risk factors: cardiovascular disease history, diabetes, arterial hypertension, dyslipidemia - Tobacco addiction. - Presenting a blood œstradiol rate > 5000 pg/ml at ovulation triggering (criterion of stimulation cancellation) and more generally, every patient which ovulation has not been triggered. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Poissy-Saint Germain Hospital | Agence de La Biomédecine |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quantification of Microparticles subsets from endothelial origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up | |
Primary | Quantification of Microparticles subsets from erythrocyte origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up | |
Primary | Quantification of Microparticles subsets from leukocyte origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal | |
Primary | Quantification of Microparticles subsets from platelet origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up | |
Primary | Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood | Venipuncture for blood sampling and exam with home made device | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal | |
Primary | Quantification of Plasmin Generation Capacity (MP-PGC) in the circulating blood | Venipuncture for blood sampling and exam with home made device | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal | |
Primary | Quantification of Fibrin monomer in the circulating blood | Venipuncture for blood sampling and exam with commercial device | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up | |
Primary | Quantification of D-dimer in the circulating blood | Venipuncture for blood sampling and exam with commercial device | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up | |
Primary | Quantification of E-selectin in the circulating blood | Venipuncture for blood sampling and exam with commercial device | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up | |
Primary | Quantification of soluble CD 146 in the circulating blood | Venipuncture for blood sampling and exam with commercial device | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up | |
Primary | Quantification of Von Willbrand factor in the circulating blood | Venipuncture for blood sampling and exam with commercial device | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up | |
Primary | Quantification of thrombin-antithrombin complex in the circulating blood | Venipuncture for blood sampling and exam with commercial device | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up | |
Primary | Quantification of prothrombin fragment 1+2 in the circulating blood | Venipuncture for blood sampling and exam with commercial device | At day 3 of an unstimulated (i.e. natural) menstrual cycle, before IVF cycle, when basal hormonal assessments is performed for fertility work-up | |
Primary | Quantification of Microparticles subsets from endothelial origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of Microparticles subsets from erythrocyte origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of Microparticles subsets from leukocyte origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of Microparticles subsets from platelet origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood | Venipuncture for blood sampling and exam with home made device | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of Plasmin Generation Capacity (MP-PGC) in the circulating blood | Venipuncture for blood sampling and exam with home made device | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of Fibrin monomer in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of D-dimer in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of E-selectin in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of soluble CD 146 in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of Von Willbrand factor in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of thrombin-antithrombin complex in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of prothrombin fragment 1+2 in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at first day of FSH stimulation | |
Primary | Quantification of Microparticles subsets from endothelial origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of Microparticles subsets from erythrocyte origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of Microparticles subsets from leukocyte origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of Microparticles subsets from platelet origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood | Venipuncture for blood sampling and exam with home made device | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of Plasmin Generation Capacity (MP-PGC) in the circulating blood | Venipuncture for blood sampling and exam with home made device | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of Fibrin monomer in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of D-dimer in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of E-selectin in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of soluble CD 146 in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of Von Willbrand factor in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of thrombin-antithrombin complex in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of prothrombin fragment 1+2 in the circulating blood | Venipuncture for blood sampling and exam with commercial device | During ovarian stimulation for IVF (first cycle), at ovarian triggering day, i.e.when = 3 ovarian follicles rich 17mm | |
Primary | Quantification of Microparticles subsets from endothelial origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of Microparticles subsets from erythrocyte origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of Microparticles subsets from leukocyte origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of Microparticles subsets from platelet origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood | Venipuncture for blood sampling and exam with home made device | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of Plasmin Generation Capacity (MP-PGC) in the circulating blood | Venipuncture for blood sampling and exam with home made device | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of Fibrin monomer in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of D-dimer in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of E-selectin in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of soluble CD 146 in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of Von Willbrand factor in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of thrombin-antithrombin complex in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of prothrombin fragment 1+2 in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 4 days after ovarian triggering for IVF (first cycle), at the day of embryo transfer of the Day 2 embryos | |
Primary | Quantification of Microparticles subsets from endothelial origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase | |
Primary | Quantification of Microparticles subsets from erythrocyte origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase | |
Primary | Quantification of Microparticles subsets from leukocyte origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase | |
Primary | Quantification of Microparticles subsets from platelet origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase | |
Primary | Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood | Venipuncture for blood sampling and exam with home made device | 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase | |
Primary | Quantification of Plasmin Generation Capacity (MP-PGC) in the circulating blood | Venipuncture for blood sampling and exam with home made device | 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase | |
Primary | Quantification of Fibrin monomer in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase | |
Primary | Quantification of D-dimer in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase | |
Primary | Quantification of E-selectin in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase | |
Primary | Quantification of soluble CD 146 in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase | |
Primary | Quantification of Von Willbrand factor in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase | |
Primary | Quantification of thrombin-antithrombin complex in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 9 days after ovarian triggering for IVF (first cycle), at mid-luteal phase | |
Primary | Quantification of Microparticles subsets from platelet origin in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of Microparticles subsets from endothelial origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of Microparticles subsets from erythrocyte origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of Microparticles subsets from leukocyte origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of Microparticles subsets from platelet origin in the circulating blood | Venipuncture for blood sampling and exam with flow cytometry | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood | Venipuncture for blood sampling and exam with home made device | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of Plasmin Generation Capacity (MP-PGC) in the circulating blood | Venipuncture for blood sampling and exam with home made device | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of Fibrin monomer in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of D-dimer in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of E-selectin in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of soluble CD 146 in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of Von Willbrand factor in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of thrombin-antithrombin complex in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test | |
Primary | Quantification of prothrombin fragment 1+2 in the circulating blood | Venipuncture for blood sampling and exam with commercial device | 16 days after ovarian triggering for IVF (first cycle), at the day of pregnancy test |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A |